Antibodies against Claudin 18.2 useful in cancer diagnosis
The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
1. An antibody selected from the group consisting of:
(i) an antibody produced by or obtainable from a clone deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 5-22A),
(ii) an antibody which is a chimerized or humanized form of the antibody under (i), and
(iii) an antibody comprising the antigen binding site of the antibody under (i), or an antigen-binding fragment of the antibody under (i) or (ii).
2. The antibody of claim 1 , wherein the antigen binding site of the antibody under (i) comprises the variable region of the antibody under (i).
3. A hybridoma deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A).
4. A method for detecting CLDN18.2 or determining the quantity of CLDN18.2 in a sample comprising the steps of:
(i) contacting a sample with the antibody or antigen-binding fragment thereof of claim 1 and
(ii) detecting the formation of a complex or determining the quantity of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2.
5. A method for determining whether cells express CLDN18.2 comprising the steps of:
contacting a cellular sample with the antibody or antigen-binding fragment thereof of claim 1 and
(ii) detecting the formation of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2 expressed by cells in said sample.
6. A method for diagnosis, detection or monitoring of cancer comprising the steps of:
contacting a biological sample with the antibody or antigen-binding fragment of claim 1 and
(ii) detecting the formation of a complex and/or determining the quantity of a complex between the antibody or the antigen-binding fragment or the conjugate and CLDN18.2.
7. A method for determining whether a cancer is treatable by a cancer therapy targeting CLDN18.2 comprising the steps of:
contacting a sample comprising cancer cells with the antibody or antigen-binding fragment thereof of claims 1 and
(ii) detecting the formation of a complex between the antibody or the antigen-binding fragment thereof and CLDN18.2.
8. A diagnostic test kit which comprises the antibody or antigen-binding fragment thereof of claim 1 .
9. A conjugate comprising an antibody or antigen-binding fragment thereof of claim 1 coupled to at least one detectable label.
10. A hybridoma or a recombinant cell capable of producing the antibody or antigen-binding fragment thereof of claim 1 .
11. An antibody produced by or obtainable from a clone deposited under the accession no. DSM ACC3144 (muAB 43-14A) or DSM ACC3143 (muAB 35-22A).